Xenetic Biosciences (XBIO) Competitors $2.89 +0.07 (+2.34%) Closing price 08/22/2025 03:19 PM EasternExtended Trading$2.91 +0.02 (+0.83%) As of 08/22/2025 06:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsOwnershipSEC FilingsShort InterestTrendsBuy This Stock XBIO vs. LSB, XFOR, PULM, HOTH, LEXX, ADAP, SYBX, EDSA, LPCN, and BLRXShould you be buying Xenetic Biosciences stock or one of its competitors? The main competitors of Xenetic Biosciences include LakeShore Biopharma (LSB), X4 Pharmaceuticals (XFOR), Pulmatrix (PULM), Hoth Therapeutics (HOTH), Lexaria Bioscience (LEXX), Adaptimmune Therapeutics (ADAP), Synlogic (SYBX), Edesa Biotech (EDSA), Lipocine (LPCN), and BioLineRx (BLRX). These companies are all part of the "pharmaceutical products" industry. Xenetic Biosciences vs. Its Competitors LakeShore Biopharma X4 Pharmaceuticals Pulmatrix Hoth Therapeutics Lexaria Bioscience Adaptimmune Therapeutics Synlogic Edesa Biotech Lipocine BioLineRx LakeShore Biopharma (NASDAQ:LSB) and Xenetic Biosciences (NASDAQ:XBIO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability. Do institutionals and insiders hold more shares of LSB or XBIO? 52.6% of LakeShore Biopharma shares are held by institutional investors. Comparatively, 15.1% of Xenetic Biosciences shares are held by institutional investors. 14.7% of Xenetic Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has stronger earnings & valuation, LSB or XBIO? Xenetic Biosciences has lower revenue, but higher earnings than LakeShore Biopharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLakeShore Biopharma$85.67M0.20-$13.93MN/AN/AXenetic Biosciences$2.50M1.78-$3.96M-$2.00-1.44 Which has more risk and volatility, LSB or XBIO? LakeShore Biopharma has a beta of 0.56, indicating that its share price is 44% less volatile than the S&P 500. Comparatively, Xenetic Biosciences has a beta of 2.31, indicating that its share price is 131% more volatile than the S&P 500. Is LSB or XBIO more profitable? LakeShore Biopharma has a net margin of 0.00% compared to Xenetic Biosciences' net margin of -126.08%. LakeShore Biopharma's return on equity of 0.00% beat Xenetic Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets LakeShore BiopharmaN/A N/A N/A Xenetic Biosciences -126.08%-54.56%-47.28% Does the media favor LSB or XBIO? In the previous week, LakeShore Biopharma had 2 more articles in the media than Xenetic Biosciences. MarketBeat recorded 3 mentions for LakeShore Biopharma and 1 mentions for Xenetic Biosciences. Xenetic Biosciences' average media sentiment score of 1.04 beat LakeShore Biopharma's score of 0.00 indicating that Xenetic Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LakeShore Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Xenetic Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer LSB or XBIO? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LakeShore Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Xenetic Biosciences 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummaryLakeShore Biopharma and Xenetic Biosciences tied by winning 6 of the 12 factors compared between the two stocks. Get Xenetic Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for XBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding XBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XBIO vs. The Competition Export to ExcelMetricXenetic BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.67M$2.53B$5.81B$9.76BDividend YieldN/A1.67%4.39%4.06%P/E Ratio-1.4422.9031.3626.05Price / Sales1.78516.56387.8788.42Price / CashN/A179.1038.0259.36Price / Book1.005.939.536.60Net Income-$3.96M$31.83M$3.26B$265.65M7 Day Performance0.91%1.89%2.14%2.00%1 Month Performance-20.71%1.62%3.22%0.46%1 Year Performance-32.88%9.25%30.18%18.88% Xenetic Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XBIOXenetic Biosciences0.9811 of 5 stars$2.89+2.3%N/A-32.9%$4.67M$2.50M-1.444Short Interest ↑LSBLakeShore Biopharma0.6231 of 5 stars$0.82flatN/A-81.4%$17.03M$85.67M0.00773XFORX4 Pharmaceuticals4.2357 of 5 stars$2.93+17.7%$71.17+2,328.9%-82.6%$16.96M$32.77M-0.2080Analyst RevisionHigh Trading VolumePULMPulmatrix0.4127 of 5 stars$4.62-1.9%N/A+144.5%$16.86M$369K-2.1320Positive NewsShort Interest ↓HOTHHoth Therapeutics2.4541 of 5 stars$1.27-1.6%$4.00+215.0%+71.3%$16.84MN/A-1.194News CoveragePositive NewsAnalyst DowngradeShort Interest ↓LEXXLexaria Bioscience3.3701 of 5 stars$0.85+1.5%$4.00+371.1%-73.8%$16.61M$460K-1.277ADAPAdaptimmune Therapeutics2.0701 of 5 stars$0.06-11.4%$1.35+2,080.1%-95.3%$16.43M$65.09M-0.10490Insider TradeGap UpHigh Trading VolumeSYBXSynlogicN/A$1.40-2.1%N/A-2.7%$16.38MN/A-0.5680Short Interest ↑Gap UpEDSAEdesa Biotech1.5323 of 5 stars$2.32+2.2%$5.00+115.5%-46.1%$16.33MN/A-1.7620LPCNLipocine2.4392 of 5 stars$2.96-1.7%$9.00+204.1%-15.3%$16.04M$11.20M-3.4010News CoverageAnalyst ForecastAnalyst RevisionBLRXBioLineRx3.3871 of 5 stars$3.74-2.3%$26.00+595.2%-87.3%$15.93M$28.94M-0.4340 Related Companies and Tools Related Companies LSB Competitors XFOR Competitors PULM Competitors HOTH Competitors LEXX Competitors ADAP Competitors SYBX Competitors EDSA Competitors LPCN Competitors BLRX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XBIO) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xenetic Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xenetic Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access